Par Pharmaceutical Pleads Guilty To Off-Label Promotion, Pays $45M In Settlements

Par Pharmaceutical Pleads Guilty To Off-Label Promotion, Pays $45M In Settlements

NEWARK, N.J. - Par Pharmaceutical Cos. Inc. on March 5 pleaded guilty to misbranding its Megace ES anti-wasting drug by promoting it for off-label use in geriatric patients and will pay $45 million to resolve criminal and civil allegations, according ...read more